The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer (NSCLC) for the first time since 1996.
Since 1996 there have been many advances in the diagnosis, screening, and treatment of lung cancer, including the important roles of PET and CT, said Dr. David Ettinger from Johns Hopkins University.
Today's clinicians also understand the importance of histology and the use of molecular diagnostic studies, he said. Systemic therapies have advanced with innovations in adjuvant and maintenance therapies, along with the use of bevacizumab and targeted therapies. Immunotherapy is poised for innovation going forward, he added.
NCCN publishes a library of 60 guidelines that cover 97% of malignant cancers. The guidelines are developed and updated through an evidence-based process wherein experts integrate clinical and scientific data with the best judgment of panel members and other experts, NCCN said.
